Stocktoria

Humacyte, Inc. HUMA

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-22

Humacyte, Inc. statistics & valuation

Market cap$191.1M
P / S93.8×
P / B61.5×
Net margin-2003.6%
FCF margin-5197.5%
Net cash$15.1M
Enterprise value USD$176.0M
Earnings yield EBIT/EV-61.4%
Return on capital-110.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-2003.60% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-5306.00% 202020212022202320242025
Return on equity (%)
-21.70% -10.20% -817.80% -1313.40% 202020212022202320242025
Shares outstanding
5.8M 103.0M 103.2M 103.7M 130.0M 193.0M 202020212022202320242025
Net debt ($)
-$187.5M -$44.9M -$15.1M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-62.40% -9.20% -5.90% -86.40% -107.90% -35.10% 202020212022202320242025
Free cash flow margin (%)
-5197.50% 202020212022202320242025
Debt / equity (×)
0.25× 11.40× 202020212022202320242025
EPS ($)
-$11.54 -$0.66 -$0.12 -$1.07 -$1.26 -$0.26 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-5306.0%—————
Net margin-2003.6%—————
FCF margin-5197.5%—————
Return on assets-35.1%-107.9%-86.4%-5.9%-9.2%-62.4%
Return on equity-1313.4%282.3%-817.8%-10.2%-21.7%19.0%
Debt / equity11.40×-0.00×——0.25×—
Current ratio3.692.404.527.8820.753.69

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.